Physician profile
Jason Nelson
NPI 1275551400
$3,738.40
in general payments reported to CMS, 2019-2025
32 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,929 · 2020: $1,056 · 2021: $195 · 2022: $84.77 · 2023: $163 · 2024: $20.30 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $753.64 | 2019-2023 | Otezla |
| Astrazeneca Pharmaceuticals LP | $410.21 | 2019-2020 | |
| Allergan, INC. | $208.77 | 2019-2020 | |
| Glaxosmithkline, LLC. | $171.35 | 2019-2020 | |
| Amarin Pharma, INC. | $170.63 | 2019-2020 | |
| Novo Nordisk INC | $165.09 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $151.63 | 2019-2020 | |
| Medtronic, INC. | $148.84 | 2021-2022 | |
| Lilly USA, LLC | $139.56 | 2019-2020 | |
| Shire North American Group INC | $127.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.27 | 2025 | |
| Alexion Pharmaceuticals, INC. | $116.24 | 2021 | |
| Janssen Pharmaceuticals, INC | $115.30 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.53 | 2019-2020 | |
| Radius Health, INC. | $98.78 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $92.29 | 2019-2025 | |
| Abbvie INC. | $88.42 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.46 | 2020 | |
| Novartis Pharmaceuticals Corporation | $82.78 | 2019-2025 | |
| Procept Biorobotics Corporation | $69.04 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.29 | 2019-2020 | |
| Astellas Pharma US INC | $51.80 | 2019-2020 | |
| Antares Pharma, INC. | $49.79 | 2019-2020 | |
| Abbott Laboratories | $24.46 | 2023 | Proclaim |
| Tris Pharma INC | $20.30 | 2024 | Dyanavel Xr |
| Kowa Pharmaceuticals America, INC. | $20.16 | 2019 | |
| Sunovion Pharmaceuticals INC. | $19.74 | 2019 | |
| Genentech USA, INC. | $18.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.82 | 2019 | |
| Scilex Pharmaceuticals INC. | $13.61 | 2019 | |
| Medtronic Vascular, INC. | $13.25 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.